The USFDA has broadened the scope of emergency use authorization (EUA) of remdesivir. According to the EUA issued in May 2020, remdesivir was allowed to be used for the treatment of hospitalized adult and pediatric patients with severe COVID-19. Now, the scope has been broadened to include all the adult and pediatric patients with laboratory-confirmed COVID-19, irrespective of the severity. Previously, considering the lack of sufficient evidence of safety and efficacy, only a narrow subset of patients was allowed treatment with remdesivir.
However, the USFDA has now opined that the currently available information is reasonable to believe that remdesivir is safe and effective for the treatment of COVID-19 in adults and pediatric patients, irrespective of the stage of infection. It believes that the known potential benefits of remdesivir outweigh the potential risks. The decision was made…
